[关键词]
[摘要]
抗血管内皮生长因子(VEGF)药物已成为治疗眼内新生血管的首选，但频繁玻璃体内注射带来的不便和并发症不容忽视，因此寻求药效持久的新型药物以减少注射次数成为必要。Brolucizumab是一种新型的小分子抗VEGF药物，具有组织穿透性强、药物浓度高、注射量较小、药效持久和注射间隔较长等优势。注册临床研究及真实世界证据显示Brolucizumab相较于阿柏西普疗效呈非劣效性； 其改善视网膜内积液/视网膜下积液能力更为显著，且可维持较长的给药间隔； 另外，Brolucizumab的安全性较高，严重不良事件如视网膜血管炎已有报告，但发生率较低。Brolucizumab为临床治疗新生血管性年龄相关性黄斑变性(nARMD)提供了新的选择。本文就Brolucizumab在nARMD治疗中的最新进展作一综述。
[Key word]
[Abstract]
Anti-vascular endothelial growth factor(anti-VEGF)drugs have become the first choice for the treatment of intraocular neovascularization, but the inconvenience and possible complications caused by frequent intravitreal injection cannot be ignored. Therefore, it is necessary to seek new drugs with long-lasting effects, so as to reduce the number of injections. Brolucizumab, a novel small molecule anti-VEGF drug, has the advantages of stronger tissue penetration, higher drug concentration, smaller injection dose, long-lasting efficacy and longer injection interval. Registered clinical studies and real-world evidence showed that Brolucizumab is non-inferior to aflibercept in efficacy, while its ability to improve intraretinal/subretinal fluid is more significant, and it can maintain a longer dosing interval. In addition, Brolucizumab is safe and has a low incidence of serious adverse events, such as retinal vasculitis reported. Brolucizumab provides a new treatment option for neovascular age-related macular degeneration(nARMD). This article reviews the latest progress of Brolucizumab in the treatment of nARMD.
[中图分类号]
[基金项目]
国家自然科学基金资助项目(No.81470654); 陕西省自然科学基金资助项目(No.2019SF-047)
